Cholecystokinin (CCK) is a neuropeptide that affects growth rate in chickens by regulating appetite. CCK peptides exert their function by binding to two identified receptors, CCKAR and CCKBR in the GI tract and the brain, respectively, as well as in other organs. In mammals, CCK/CCKAR interactions affect a number of immunological parameters, including regulation of lymphocytes and functioning of monocytes.

CCK, also known as pancreozymin, is synthesized and secreted by enteroendocrine cells in the duodenum. The main function of CCK is to cause the release of digestive enzymes and bile from the pancreas and gallbladder, respectively. It also induces drug tolerance to opioids like morphine and heroin. Cholecystokinin (CCK) has strong bioactivity in the regulation of a number of cell activities.
Cholecystokinin Receptor Inhibitors & Modulators

CCK-A receptor inhibitor 1

Bioactivity: CCK-A receptor inhibitor 1 is a cholecystokinin A (CCK-A) receptor inhibitor with a binding \( IC_{50} \) of 340 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

CCK-B Receptor Antagonist 1

Bioactivity: CCK-B Receptor Antagonist 1 is an antagonist of cholecystokinin B (CCK-B) receptor, and has the potential of reducing the secretion of gastric acid.

Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM x 1 mL in DMSO,
1 mg, 5 mg, 10 mg,
25 mg, 50 mg

Ceruletide
(Caerulein; Cerulein; FI-6934)

Bioactivity: Ceruletide, a biologically active decapeptide isolated from the skin of the Australian frog Hyla caerulea, is a potent cholecystokinetic agent, and acts as a cholecystokinin receptor agonist.

Purity: 99.96%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

CHEMBL333994
(FK-480)

Bioactivity: CHEMBL333994 is a potent and orally effective Cholecystokin A (CCK-A) antagonist, with an \( IC_{50} \) of 0.67 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg

Gastrin-1, human

Bioactivity: Gastrin-1, human is the endogenous peptide produced in the stomach, and increases gastric acid secretion via cholecystokinin 2 (CCK2) receptor.

Purity: 98.14%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Gastrin/CCK antagonist 1

Bioactivity: Gastrin/CCK antagonist 1 is an antagonist of gastrin/CCK for the research of gastrointestinal disorders.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

GI 181771

Bioactivity: GI 181771 is a cholecystokinin 1 receptor agonist investigated for the treatment of obesity.

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

Loxiglumide
(CR-1505)

Bioactivity: Loxiglumide is a cholecystokinin (CCK-1) receptor antagonist.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10 mM x 1 mL in DMSO,
10 mg, 50 mg, 100 mg

Mini Gastrin I, human

Bioactivity: Mini Gastrin I, human is a shorter version of human gastrin 1, consists of amino acids 5-17 of the parent peptide, and binds with the CCK2i4svR.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Nastorazepide
(Z-360)

Bioactivity: Nastorazepide (Z-360) is a selective, orally available, 1,5-benzodiazepine-derivative gastrin/cholecystokinin 2 (CCK-2) receptor antagonist with potential antineoplastic activity.

Purity: >98.89%
Clinical Data: Phase 2
Size: 10 mM x 1 mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg
<table>
<thead>
<tr>
<th>Name</th>
<th>Cat. No.</th>
<th>Purity</th>
<th>Clinical Data</th>
<th>Size</th>
<th>Bioactivity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Proglumide</td>
<td>HY-81330</td>
<td>&gt;98%</td>
<td>No Development Reported</td>
<td>10mM x 1mL in DMSO, 100 mg</td>
<td>Proglumide is a known cholecystokinin (CCK) antagonist.</td>
</tr>
<tr>
<td>Sograzepide (Netazepide; YF 476; YM-220)</td>
<td>HY-14850</td>
<td>98.01%</td>
<td>No Development Reported</td>
<td>5 mg, 10 mg, 50 mg, 100 mg</td>
<td>Sograzepide (Netazepide; YF 476) is a gastrin/cholecystokinin 2 receptor (CCK2) antagonist.</td>
</tr>
<tr>
<td>SR 146131</td>
<td>HY-11077</td>
<td>&gt;98%</td>
<td>No Development Reported</td>
<td>250 mg, 500 mg</td>
<td>SR 146131 is a potent, orally available, and selective nonpeptide (cholecystokinin 1) receptor agonist.</td>
</tr>
<tr>
<td>Tarazepide</td>
<td>HY-U0062</td>
<td>&gt;98%</td>
<td>No Development Reported</td>
<td>1 mg, 5 mg, 10 mg, 20 mg</td>
<td>Tarazepide is a potent and specific CCK-A receptor antagonist.</td>
</tr>
</tbody>
</table>